Literature DB >> 6703503

Experimental chemotherapy in chronic Mycobacterium avium-intracellulare infection of mice.

F Kuze.   

Abstract

The effects of various chemotherapeutic regimens were investigated in ddY mice infected intravenously with a mouse-virulent strain, 31F093T, of Mycobacterium avium-intracellulare. Evaluation of therapeutic effects was based on serial counts of viable bacilli in the lung, the spleen, and the kidney, as well as on weight and extent of gross diseases of the organs, and on histopathologic examination. Kanamycin alone was effective against the infection. The combination of ethambutol and rifampin with kanamycin (KM-EMB-RMP) decreased counts in the lung. In another 3-drug regimen (kanamycin, ethionamide, and cycloserine), the effect was similar. Two 4-drug regimens, KM-EMB-RMP-CEX and KM-EMB-RMP-MINO, as well as a 5-drug regimen, KM-EMB-RMP-CS-INH, were also compared with the above 3-drug regimens, and only the 5-drug regimen decreased counts in the lung more than the 3-drug regimens did. Even the 5-drug regimen, however, could not eradicate the mycobacteria in the organs of mice, which demonstrates the inveteracy of M. avium-intracellulare infection. The control mice consistently showed grossly visible disease of the lung at 6 wk of infection, and the histopathologic findings were granuloma (3 to 6 wk of infection) and diffuse proliferative change beyond 9 weeks of infection, which was persistent and slowly progressive. The spleens and livers showed extensive granulomatous changes. The subacuteness of grossly visible lung disease with significant multiplication of bacilli in the organ of the control mice in the present murine model should prove useful in evaluating experimental chemotherapy of M. avium-intracellulare infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703503     DOI: 10.1164/arrd.1984.129.3.453

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

Review 1.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

2.  Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

Authors:  S E Hoffner; S B Svenson; G Källenius
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

Review 3.  Beige mouse model for Mycobacterium avium complex disease.

Authors:  P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

4.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  M H Cynamon; C E Swenson; G S Palmer; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice.

Authors:  T Yamamoto; R Amitani; K Suzuki; E Tanaka; T Murayama; F Kuze
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex.

Authors:  K Suzuki; W J Lee; T Hashimoto; E Tanaka; T Murayama; R Amitani; K Yamamoto; F Kuze
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

8.  Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis.

Authors:  T Doi; M Ando; T Akaike; M Suga; K Sato; H Maeda
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.